top of page

Alopecia Help

MCT vs PRP for Hair Loss: Why We Don’t Use Meta Cell Technology at Growth Factor Hair Clinic

Writer: Gwen Adey
Gwen Adey
9 minutes ago
3 min read

A couple of years ago, something called Meta Cell Technology (MCT) arrived on the scene, and a few patients started asking us about it.


MCT was being promoted as a newer, more advanced form of platelet-rich plasma (PRP) treatment for hair loss.


The idea was that exposing PRP to light and controlled cooling before injecting it into the scalp might make the treatment more effective.

We looked into it at the time, but weren’t convinced.


Light and temperature might influence platelet activity and growth factor release, but would this actually improve hair growth? Or might it make no difference? Or could it even give poorer result?


Without convincing clinical evidence of an additional benefit, we decided not to introduce MCT.


Now, a newly published clinical trial has directly compared conventional PRP with MCT-treated PRP.


And the researchers found no statistically significant advantage from the additional MCT processing.


What did the researchers do?


The study, published in November 2026 in Photodermatology, Photoimmunology & Photomedicine, involved 21 adults with male or female pattern hair loss.


Researchers used a randomised, double-blind, split-scalp design. One half of each participant’s scalp received conventional PRP, while the other received PRP processed using Meta Cell Technology.


The MCT preparation was exposed to red light for 15 minutes, with the device temperature set to 4°C.


Participants received four treatments, spaced four weeks apart, and their hair was assessed over 24 weeks.


What were the results?


Both sides of the scalp showed improvements in several hair measurements.


However, there was no statistically significant difference between conventional PRP and MCT-treated PRP in hair density, non-vellus hair density or hair shaft diameter.


The researchers found no significant difference in treatment-related pain either.

In other words, adding the light and cooling stage did not demonstrate any additional clinical benefit.


But wasn’t this a small study?


Yes. Only 21 participants were enrolled, with 19 completing the final assessment.


Although the split-scalp design is a strength, the small sample size means that a modest difference between treatments could have been missed.


The study also had no untreated comparison area, so it cannot establish precisely how much of the improvement was attributable to PRP itself.


We therefore cannot conclude that the two treatments are equally effective, or that MCT has no benefit.


Nevertheless, this study does not support claims that the MCT preparation tested produces better hair growth than conventional PRP.


Why we don’t use MCT at Growth Factor Hair Clinic


At Growth Factor Hair Clinic, we’re always interested in developments that might improve treatment outcomes.


But newer doesn’t automatically mean better.


There is laboratory evidence suggesting that light and temperature can influence platelet activity and growth factor release. However, changes observed in a laboratory don’t necessarily translate into better results for patients.


We believe that when an additional processing step is proposed as an improvement on an existing treatment, its clinical benefits should be demonstrated rather than assumed.


We decided against introducing MCT because we weren’t persuaded that the evidence justified it.


This new study hasn’t given us a reason to change that decision.


We’re not suggesting that MCT cannot work, or that future research won’t identify benefits. We’re saying that there is currently insufficient clinical evidence for us to choose it over conventional PRP for hair loss treatment.


Authored by: Dr Gwen Adey

First Published: 15/11/26


Research reference

Charoensuksira S, Siriphanit R, Valerie C, et al. (2026).

Photo- and Temperature-Conditioned Versus Conventional Platelet-Rich Plasma for Androgenetic Alopecia: A Split-Scalp, Double-Blind, and Randomized Active-Comparator Trial.

Photodermatology, Photoimmunology & Photomedicine, 42, e70139.

bottom of page